SELB SELECTA BIOSCIENCES

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 8768458. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, .

About Selecta Biosciences, Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit .

For Investors:

Bruce Mackle

LifeSci Advisors, LLC



For Media: 

Brittany Leigh, Ph.D.

LifeSci Communications, LLC





EN
23/02/2023

Underlying

SELBSELECTA BIOSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SELECTA BIOSCIENCES

 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company’s common stock with an exercise price of $6.39, the closing trading price of the Company’s common stock on the Nasdaq Global Market...

April 2, 2026 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Pr...

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA...

March 9, 2026 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March and April: A presentation at the 46th Annual TD Cowen Health Care Conference at 11:50 a.m. ET Monday, March 2, 2026A fireside chat at Leerink’s Global Healthcare Conference at 10:00 a.m. ET on Monday, March 9, 2026A fi...

February 23, 2026 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company’s common stock with an exercise price of $6.79, the closing trading price of the Company’s common stock on the Nasdaq Global Market on...

February 3, 2026 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Ou...

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., ...

January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch